VSV-hIFNbeta
AXP000136.1 · Oncolytic virus
- Platform
- vesicular stomatitis virus (Indiana serotype, human IFN-beta-armed)
- Originator
- Mayo Clinic
- Sponsor
- Mayo Clinic
Names
| Name | Type | Source |
|---|---|---|
| VSV-hIFNbeta | preferred name, code | curator, ncit |
| Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta | synonym | ncit |
| VSV-hIFN-b | synonym | ncit |
| VSV-IFN-beta ambiguous | synonym | ncit |
Virus
- Role
- Oncolytic
- Family
- Rhabdoviridae
- Virus
- vesicular stomatitis Indiana virus (NCBI Taxonomy 11277)
- Strain
- Indiana, recombinant
- Replication
- replicating
- Modifications
- human interferon beta cassette inserted; no NIS cassette
- Transgenes
- IFNB1
- Route
- intratumoral, intra arterial
- Source
- evidence
Cross-references
- NCI Thesaurus
- C102545
Approvals
No regulatory approval recorded.
Clinical trials (6)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07510334 | VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma | Recruiting | Phase 2 | 2026-04-21 | 2033-08-01 | 18 | Advanced Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8 |
| NCT06508463 | Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma | Recruiting | Phase 1 | 2024-01-05 | 2028-12-31 | 21 | Anaplastic Large Cell Lymphoma; Mycosis Fungoides; Peripheral T Cell Lymphoma; Peripheral T-Cell Lymphoma, Not Otherwise Specified; Relapsed Anaplastic Large Cell Lymphoma; Relapsed Mycosis Fungoides; Relapsed Peripheral T-Cell Lymphoma |
| NCT03865212 | Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma | Terminated | Phase 1 | 2019-06-12 | 2025-10-12 | 12 | Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Choroid Melanoma; Metastatic Melanoma; Metastatic Mucosal Melanoma; Metastatic Uveal Melanoma; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Unresectable Melanoma |
| NCT03120624 | VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer | Active not recruiting | Phase 1 | 2017-09-15 | 2023-08-29 | 34 | Metastatic Endometrial Carcinoma; Recurrent Endometrial Adenocarcinoma; Recurrent Endometrial Carcinoma; Recurrent Endometrial Clear Cell Adenocarcinoma; Recurrent Endometrial Endometrioid Adenocarcinoma; Recurrent Endometrial Mixed Cell Adenocarcinoma; Recurrent Endometrial Serous Adenocarcinoma; Recurrent Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinosarcoma; Stage IV Uterine Corpus Cancer AJCC v7 |
| NCT03017820 | A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma | Recruiting | Phase 1 | 2017-04-04 | 2028-12-31 | 99 | B-Cell Non-Hodgkin Lymphoma; Histiocytic and Dendritic Cell Neoplasm; Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome; Recurrent Adult Acute Myeloid Leukemia; Recurrent Anaplastic Large Cell Lymphoma; Recurrent Angioimmunoblastic T-Cell Lymphoma; Recurrent Mycosis Fungoides; Recurrent Plasma Cell Myeloma; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Recurrent T-Cell Non-Hodgkin Lymphoma; Refractory Acute Myeloid Leukemia; Refractory Anaplastic Large Cell Lymphoma; Refractory Angioimmunoblastic T-Cell Lymphoma; Refractory Mycosis Fungoides; Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified; Refractory Plasma Cell Myeloma; Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory T-Cell Non-Hodgkin Lymphoma |
| NCT01628640 | Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors | Completed | Phase 1 | 2012-08-03 | 2019-04-19 | 17 | Advanced Malignant Solid Neoplasm; Hepatocellular Carcinoma |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 36052732 | Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers. | Hepatology (Baltimore, Md.) | 2023 | cited by trial NCT01628640 |
| PMID 36898933 | Nodal peripheral T-cell lymphoma: Chemotherapy-free management, are we there yet? | Blood reviews | 2023 | cited by trial NCT03017820 |
| PMID 35175355 | Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma. | Blood advances | 2022 | cited by trial NCT03017820 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 19911974 | Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates. | Human gene therapy | 2010 | name in abstract: VSV-hIFNbeta |
| PMID 12885903 | Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. | Journal of virology | 2003 | name in abstract: VSV-hIFNbeta |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| DP2CA195764 | Oncolytic Virotherapy in Hepatocellular Cancer | MAYO CLINIC ARIZONA | BORAD, MITESH | 2014–2016 | name in abstract: VSV-hIFN-b |
| R01FD004781 | Phase 1 Study of VSV-hIFN-B for the Treatment of Hepatocellular Carcinoma | MAYO CLINIC ARIZONA | BORAD, MITESH | 2014–2016 | name in title: VSV-hIFN-b |
Notes
Recombinant VSV expressing human interferon beta WITHOUT the sodium iodide symporter, i.e. the construct preceding VSV-IFNbeta-NIS (AXP000119). NCIt keeps the two apart (C102545 vs C131580). Dosed intratumorally and intrahepatically in the completed Mayo phase 1 NCT01628640 (2012-2019) in hepatocellular carcinoma and other solid tumours.
How to cite
VSV-hIFNbeta (AXP000136.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000136.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.